在结直肠癌存活率中对regorafenib和免疫治疗进行比较:一个多中心队列研究
Uzma Farzana1, Raphael E Cuomo1
1University of California, San Diego, School of Medicine, San Diego, CA, USA.
Cancer treatment and research communications
|February 19, 2026
概括
免疫检查点抑制剂 (ICI) 与结直肠癌 (CRC) 患者在化疗后的regorafenib相比改善了生存率. 治疗后的癌胚抗原 (CEA) 水平也不同,这表明预后价值.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 癌症治疗方法 癌症治疗方法
背景情况:
- 有限的现实数据比较了化疗后结直肠癌 (CRC) 中的regorafenib和免疫检查点抑制剂 (ICI).
- 了解比较疗效对于治疗决策至关重要.
研究的目的:
- 为了比较regorafenib与ICI在之前接受化疗的CRC患者的实际结果.
- 评估两个治疗组之间的整体存活率和预后标志物.
主要方法:
- 从2012-2025年对非识别的EHR数据进行了回顾性分析.
- 通过使用时间到事件分析进行化学治疗后开始使用regorafenib (C/R) 或ICI (C/I) 的患者进行比较.
- 使用了卡普兰-梅尔,多变量考克斯模型,受限平均存活时间 (RMST) 和倾向得分重叠加权分析.
主要成果:
- 五年存活率高于ICI (41.5%) 与regorafenib (33.2%) 相比.
- 雷戈拉费尼布与死亡风险增加有关 (HR 1.217,p=0.0282).
- ICI显示优异的3年和5年的RMST;治疗后CEA在regorafenib组中更高 (p<0.0001).
结论:
- 在化疗后启动ICI与与regorafenib相比,与CRC的存活率提高有关.
- 治疗后的CEA水平在治疗组之间有所不同,这表明潜在的预后价值.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...